https://www.selleckchem.com/products/AZD2281(Olaparib).html HBsAg decline in HBeAg patients treated with NAs or PEG-IFN was 0.418 or 1.217 log IU/mL (P<0.0001) at week 48; whereas HBsAg decline was 0.176 or 0.816 log IU/mL (P<0.001) in HBeAg patients. HBsAg at baseline and week 24 were strong predictors of "low HBsAg at week 48". Long term anti-viral therapy inhibits HBV replication effectively in ALT<2×ULN CHB patients. PEG-IFN therapy is recommended for HBeAg patients with baseline HBsAg<4.37 log IU/ml and HBeAg patients with baseline HBsAg<2.66 log IU/ml to achieve "low HBsAg at week 48". Long term anti-viral therapy inhibits HBV replication effectively in ALT less then 2 × ULN CHB patients. PEG-IFN therapy is recommended for HBeAg+ patients with baseline HBsAg less then 4.37 log IU/ml and HBeAg- patients with baseline HBsAg less then 2.66 log IU/ml to achieve "low HBsAg at week 48".Interaction of follicle stimulating hormone (FSH) with its cognate receptor (FSHR) is critical for maintaining reproductive health. FSHR has a large extracellular domain (ECD), composed of leucine rich repeats (LRRs) and hinge region, a transmembrane domain (TMD) and a short C-terminal domain (CTD). In this study, we have identified a short peptidic stretch in the hinge region (hFSHR(271-275)), through extensive computational modeling, docking and MD simulations, that is capable of independently interacting with the extracellular loops of FSHR(TMD). In vitro studies revealed that FSHR(271-275) peptide increased binding of [125I]-FSH to rat Fshr as well as FSH-induced cAMP production. Administration of FSHR(271-275) peptide in immature female rats significantly increased FSH-mediated ovarian weight gain and promoted granulosa cell proliferation. In summary, the results demonstrate that the synthetic peptide corresponding to amino acids 271-275 of hFSHR-hinge region stimulates FSH-FSHR interaction and behaves as positive allosteric modulator of FSHR. The study also lends evidence to the